Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Short term Debt (2020 - 2022)

RedHill Biopharma has reported Short term Debt over the past 3 years, most recently at $115.2 million for Q4 2022.

  • Quarterly Short term Debt rose 37.79% to $115.2 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $115.2 million through Dec 2022, up 37.79% year-over-year, with the annual reading at $115.2 million for FY2022, 37.79% up from the prior year.
  • Short term Debt was $115.2 million for Q4 2022 at RedHill Biopharma, up from $113.9 million in the prior quarter.
  • Over five years, Short term Debt peaked at $115.2 million in Q4 2022 and troughed at $78.2 million in Q1 2020.
  • The 3-year median for Short term Debt is $83.3 million (2021), against an average of $87.7 million.
  • Year-over-year, Short term Debt grew 2.74% in 2021 and then surged 37.79% in 2022.
  • A 3-year view of Short term Debt shows it stood at $81.4 million in 2020, then increased by 2.74% to $83.6 million in 2021, then skyrocketed by 37.79% to $115.2 million in 2022.
  • Per Business Quant, the three most recent readings for RDHL's Short term Debt are $115.2 million (Q4 2022), $113.9 million (Q3 2022), and $85.5 million (Q2 2022).